Monoclonal Antibodies & Therapeutics
Monoclonal antibodies (mAbs) remain at the forefront of biologic therapeutics, with broad applications in oncology, autoimmune diseases, and infectious conditions. This session will delve into the latest advancements in mAb discovery, humanization, glycoengineering, and conjugation techniques. Topics include bispecific and multispecific antibodies, antibody-drug conjugates (ADCs), and mechanisms to improve specificity, half-life, and tissue targeting. Manufacturing scalability, immunogenicity mitigation, and regulatory approval pathways for both originator mAbs and biosimilar versions will be explored. Participants will also gain insights into clinical development trends, including combination therapies, dosing innovations, and real-world applications of mAbs in chronic disease management. Designed for researchers, clinicians, and developers, this session bridges fundamental science with translational and clinical outcomes to highlight the full potential of monoclonal antibody therapeutics.